Compare WIA & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | ORMP |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 170.3M |
| IPO Year | N/A | 2010 |
| Metric | WIA | ORMP |
|---|---|---|
| Price | $7.95 | $4.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.0K | ★ 173.4K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 12.29% | 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.82 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $7.90 | $1.98 |
| 52 Week High | $8.54 | $5.19 |
| Indicator | WIA | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 55.45 |
| Support Level | N/A | $3.90 |
| Resistance Level | $8.31 | $5.10 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 21.06 | 95.00 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.